Participated in Timberlyne Therapeutics' $180M Series A financing to advance CM313, an anti-CD38 monoclonal antibody.
Timberlyne Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of transformational therapies for autoimmune diseases
Timberlyne Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of transformational therapies for autoimmune diseases. The company is leveraging drug development expertise to acquire best-in-class assets and apply them to disease areas with significant unmet need.